Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Pacific Biometrics, Inc.

This article was originally published in The Gray Sheet

Executive Summary

Pacific Biometrics, Inc.: Completes pilot clinical studies on its non-invasive Osteopatch used in the diagnosis of osteoporotic disease. The patch is affixed to the patient's skin to collect sweat samples, which are used in "the dectection of biochemical markers of bone loss," the Irvine, California firm says. Pacific Biometrics has signed up several U.S. medical centers as sites for its upcoming clinical trials, which are expected to include 300 subjects. The company plans to submit a 510(k) once the studies are completed...

You may also be interested in...



Celltrion Makes Progress On Coronavirus Treatment

Celltrion has accelerated the development of its antiviral treatment for COVID-19 and aims to launch a rapid self-testing kit that could provide results within 15-20 minutes. The Korean firm also plans to develop a ‘super antibody’ to prepare for potential future pandemic situations.

Spain Lists Certain OTCs As 'Essential' In Fight Against COVID-19

Paracetamol, acetylcysteine and loperamide among list of OTC drugs deemed "essential" by Spain in the fight against coronavirus.

Mylan And Lupin Get EU Etanercept Nod

Mylan, in partnership with Indian firm Lupin, will be looking to rival Biogen and Sandoz by introducing an etanercept biosimilar in European markets following a positive opinion by the EMA’s CHMP on Mylan's application.

UsernamePublicRestriction

Register

MT008689

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel